Head-to-head · WeighScore
AbundRX vs Boston Medical Group
The verdict
AbundRX takes it — 66.6/100 to 61.9/100.
AbundRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. AbundRX (Abundant Wellness) is an online medical weight-care platform connecting patients with licensed clinicians for compounded GLP-1 treatment.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | AbundRX | Boston Medical Group |
|---|---|---|
| WeighScore | 66.6/100 | 61.9/100 |
| Grade | C | C |
| Scorecard rank | #181 | #279 |
| Semaglutide | $179/mo (compounded) | $199/mo (starting strength, rising with dose, compounded) |
| Tirzepatide | $279/mo (compounded) | Not disclosed |
| Coverage | Coverage not published | 7 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #181 · C
Strengths
- Two clear compounded GLP-1 pathways with transparent pricing — semaglutide $179/mo and tirzepatide $279/mo
- Fast, free shipping and a simple few-minute online health assessment
- Provider-guided care connecting patients with licensed US clinicians
- Publishes Terms, Privacy, and Refund policies
Where it loses points
- Claims LegitScript certification in text but displays no verifiable seal or listing
- Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
- Compounding pharmacy not named; no HIPAA notice found; state availability not published
- Heavily hedged marketing language ('may include', 'helping connect patients') — reads like a lead-generation platform
Graded #279 · C
Strengths
- An established medical group with a defined 12-week programme rather than an open-ended subscription
- The price range and the 12-week total are both published, once you reach the costs page
- Semaglutide is prescribed and dispensed under a compounded pathway with clinician oversight
Where it loses points
- The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
- The 12-week programme totals $699 including a telemedicine platform fee that is never itemised — about $233/mo all-in, not $199
- The weight-loss landing page carries no price at all; the numbers are two pages deeper, in the FAQ and the costs page
- Semaglutide and tirzepatide are not priced separately — one range covers the whole programme
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.